Activity value 80south korea Buyer&Supplier,Last transaction date:
2026-05-27
Overview
Export data
Partners
HS Codes
Products
Areas
Ports
Trade trend analysis
Mon
|
Year
Number of TransactionsQuantityWeight
Number of TransactionsQuantityWeight
The above chart presents the market trend analysis for myungmoon pharma co.ltd. from 2025 to 2026.
By examining various dimensions such as transaction quantity, transaction weight, average price,
and transaction frequency, we can gain an intuitive understanding of the company's performance in terms of procurement cycles, business scale, and stability.
As of 2026, the company has completed 3 transactions, with a transaction quantity of 798.33 and a transaction weight of 634.36.
YearTransactionsQuantityWeight
202543774.614499.99
20263798.33634.36
Bill of lading data
<
1/15
>
Trade date
2026/05/27
B/L No.
086387
Suppliers
myungmoon pharma co.ltd.
Buyers
no disponible
Product description
RIVASTIGMINE [ PH.EUR ] ( BATCH NO BR - 011/24 ) { IMPORT FOR RE - PROSSCESS AND RE - EXP- SB NO 2351408 DT 11-07-2024 }RIVASTIGMINE PH.EUR ( BATCH NO BR - 011/24 ) IMPORT FOR RE -
Expand
myungmoon pharma co.ltd. is south korea Buyer&Supplier,
and primarily engages in the import and export business of products such as box,bat,medicine.
According to the 52wmb.com global trade database, as of 2026-05-27, the company has completed 1425 international trades,
with its main trading regions covering pakistan,philippines,peru etc.
The core products include HS30049099,HS30044990000,HS30042099000 etc,
often transported via busan,port doha qatar, port pipavav etc,
and its main trading partners are aster life sciences,hoffman human health pakistan,allied distributors.
These trade data are sourced from various countries' customs and public channels, and have undergone standardization and structuring processing.
They can reflect the import and export trends and main market layout of the enterprise, and are suitable for market trend analysis, competitor research, port transportation planning, supply chain optimization, and international customer development.
They provide reliable support for cross-border trade decision-making.
The trade data displayed on myungmoon pharma co.ltd. is sourced from the 52wmb.com global trade database. It is based on legal records from customs and related public channels of various countries, and has been formatted and organized for user query and analysis.
We maintain compliance with the source and processing of data to ensure the objectivity of information, but due to the dynamic changes in international trade activities, some data may be delayed or changed.